Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANI Pharmaceuticals

66.30
-5.2300-7.31%
Post-market: 66.300.00000.00%19:06 EDT
Volume:756.75K
Turnover:51.64M
Market Cap:1.43B
PE:-63.57
High:77.00
Open:76.01
Low:65.96
Close:71.53
Loading ...

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast

Benzinga
·
28 Feb

Stock Track | ANI Pharmaceuticals Surges 14.73% on Record Q4 Earnings Fueled by Rare Disease Drug Growth

Stock Track
·
28 Feb

ANI Pharmaceuticals Shares Jump on 4Q Beat, Upgraded 2025 Targets

Dow Jones
·
28 Feb

ANI Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

ANI (ANIP) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks
·
28 Feb

BUZZ-ANI Pharma rises as rare-disease drugs drive quarterly results beat

Reuters
·
28 Feb

ANI Pharmaceuticals Shares Jump 15.4% Premarket After Raising 2025 Outlook

THOMSON REUTERS
·
28 Feb

ANI Pharmaceuticals Files Form 8-K with SEC

TIPRANKS
·
28 Feb

ANI: Q4 Earnings Snapshot

Associated Press Finance
·
28 Feb

ANI Pharmaceuticals' Q4 Adjusted Earnings, Revenue Rise; Provides 2025 Outlook

MT Newswires Live
·
28 Feb

ANI Pharmaceuticals Expects 2025 Adjusted EPS Of $6.12-$6.49 Versus Consensus Of $5.56

Benzinga
·
28 Feb

ANI Pharmaceuticals Expects 2025 Revenues Of $756M-$776M Versus Prior Guidance Of $739M-$759M And Consensus Of $724.71M, With Adjusted EBITDA Of $190M-$200M Compared To Prior Guidance Of $182M-$192M

Benzinga
·
28 Feb

Stock Track | ANI Pharmaceuticals Soars 8.08% in Pre-market on Impressive Q4 Earnings Beat

Stock Track
·
28 Feb

ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars

StockStory
·
28 Feb

ANI Pharmaceuticals Q4 2024 Adj EPS $1.63 Beats $1.44 Estimate, Sales $190.57M Beat $175.37M Estimate

Benzinga
·
28 Feb

BRIEF-ANI Pharmaceuticals Q4 Revenue USD 87.043 Million Vs. IBES Estimate USD 175.4 Million

Reuters
·
28 Feb

ANI Pharmaceuticals Inc: Outlook FY25 REV $756.0 Mln to $776.0 Mln

THOMSON REUTERS
·
28 Feb

ANI Pharmaceuticals Outlook FY Adjusted EPS USD 6.12-6.49

THOMSON REUTERS
·
28 Feb

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

THOMSON REUTERS
·
28 Feb

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

StockStory
·
21 Feb